encaleret
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Sep 15, 2020 (NCT04581629)
Timeline
Indications
Mechanism of action
- Calcium sensing receptorANTAGONIST
CASR antagonist
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cc(-c2ccccc2[C@@H](C)OC[C@H](O)CNC(C)(C)Cc2ccc(Cl)c(F)c2)ccc1C(=O)O- Mol. weight
- 514.04 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1672973 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07080385 | Phase 2/Phase 3 (Phase 3) | Aug 31, 2025 | Calcilytix Therapeutics, Inc. |
| NCT05735015 | Phase 2 | Sep 22, 2023 | National Institute of Dental and Craniofacial Research (NIDCR) |
| NCT05680818 | Phase 3 | Jan 6, 2023 | Calcilytix Therapeutics, Inc. |
| NCT04581629 | Phase 2 | Sep 15, 2020 | Calcilytix Therapeutics, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Calcilytix Therapeutics, Inc. | For profit | 3 | 3 | 2 | 2020 |
| National Institute of Dental and Craniofacial Research (NIDCR) | Government | 1 | 1 | 1 | 2023 |
2 organizations
Page 1 / 1